Safety and Effectiveness Study for a Needle Guidance System in Lung Biopsies

NCT ID: NCT01183182

Last Updated: 2012-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to provide clinical data regarding safety and clinical effectiveness of the ActiSight Needle Guidance System in assisting radiologically guided percutaneous needle biopsy or aspiration of pulmonary lesions, which is a common procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a prospective, single-arm study. At least three centers in Canada will participate in the study and at least 4 different experienced staff radiologists will perform the procedures for the study.

A total of forty eight (48) consecutive subjects meeting the eligibility criteria, scheduled for clinically indicated CT guided lung biopsy or aspiration procedure at the participating centers will be invited to enroll in the study. To ensure diversity in the study population, consecutive patients will be enrolled in the following groups until these groups are fully enrolled:

Lesion size ≥1.0 cm and ≤ 1.5 cm: 10 patients; Lesion size \>1.5 and ≤ 3.0 cm: 19 patients; Lesion size \>3.0 cm: 19 patients.

A maximum of 24 patients will be enrolled at each center.

Informed consent will be signed prior to the procedure. Subject data collection on the day of the procedure will include demographics, relevant medical history and vital signs. Enrolled subjects will undergo CT guided percutaneous lung aspiration and/or biopsy as clinically indicated by a qualified physician, utilizing the ActiSight Needle Guidance System. Subjects will be followed-up as outlined below to assess adverse events related to the procedure. A subject's enrollment in the study will be completed after the follow-up visit or after resolution of any procedure related adverse event.

A procedure difficulty classification is defined for this study, based on existing literature. Difficulty levels for all procedures will be recorded and included in the final report.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Lung nodule Lung lesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Needle Guidance

Lung biopsies performed with the needle guidance system.

Group Type EXPERIMENTAL

ActiSight Needle Guidance System

Intervention Type DEVICE

Three different groups of patients defined per lesion size

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ActiSight Needle Guidance System

Three different groups of patients defined per lesion size

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CT-Guide Needle Guidance System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects, 18 years of age or older at the time of enrollment;
* Subjects scheduled for clinically indicated CT guided percutaneous lung aspiration/biopsy;
* Written informed consent to participate in the study;
* Ability to comply with the requirements of the study procedures;
* Verified home address and phone number to facilitate study follow-up.

Exclusion Criteria

* Significant coagulopathy that cannot be adequately corrected;
* Subjects who participated in an active stage of any drug, intervention or treatment trial within 30 days of enrollment;
* Subjects with preexisting conditions which, in the opinion of the investigator, interfere with the conduct of the study;
* Subjects who are uncooperative or cannot follow instructions;
* Mental impairment that may preclude completion of the study procedure;
* Pregnant or nursing female subjects.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ActiViews Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Narinder, MD

Role: PRINCIPAL_INVESTIGATOR

University Health Network, Toronto

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status

University Health Network, Toronto General Hospital

Toronto, Ontario, Canada

Site Status

McGill University Health Center, Royal Victoria Hospital, Montreal General Hospital

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACST-2010-1

Identifier Type: -

Identifier Source: org_study_id